DDInter1607 DDInter424
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Ritonavir {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Ritonavir {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Ritonavir {u} (Compound) causes {v} (Side Effect) Peripheral vascular disorder
Peripheral vascular disorder {u} (Side Effect) is caused by {v} (Compound) Propafenone
Propafenone {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Saquinavir
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ritonavir (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ritonavir (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Aprepitant (Compound) and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ritonavir (Compound) causes Peripheral vascular disorder (Side Effect) and Peripheral vascular disorder (Side Effect) is caused by Propafenone (Compound) and Propafenone may lead to a major life threatening interaction when taken with Cobicistat
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may lead to a major life threatening interaction when taken with Cobicistat
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Cobicistat